Clearside Biomedical, Inc. (CLSD) News

Clearside Biomedical, Inc. (CLSD): $1.55

0.09 (+6.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CLSD News Items

CLSD News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CLSD News Highlights

  • CLSD's 30 day story count now stands at 3.
  • Over the past 12 days, the trend for CLSD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • SCS and EYE are the most mentioned tickers in articles about CLSD.

Latest CLSD News From Around the Web

Below are the latest news stories about Clearside Biomedical Inc that investors may wish to consider to help them evaluate CLSD as an investment opportunity.

Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference

- Suprachoroidal Injection Platform Facilitates Targeted Delivery of Therapeutic Agents to the Retina and Choroid -ALPHARETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral presentations on Clearside’s SCS injection platform featuring the SCS Microinjector® were given at the Bascom Palmer Eye I

Yahoo | February 14, 2022

The past five years for Clearside Biomedical (NASDAQ:CLSD) investors has not been profitable

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we see...

Yahoo | February 11, 2022

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference on February 12, 2022

Clearside’s suprachoroidal space (SCS®) injection platform to be featured at top medical meeting and also at Raymond James Angiogenesis Preview EventALPHARETTA, Ga., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS), announced today that Clearside’s SCS injection platform featuring the SCS Microinjector® will be featured in multiple oral p

Yahoo | February 2, 2022

7 of the Best Penny Stocks Under $3 for 2022 to Buy Now

Penny stocks under $3 are full of potential and potential pitfalls.

Alex Sirois on InvestorPlace | December 31, 2021

Clearside Biomedical (CLSD) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report) today and set a price target of $10.00. The company's shares closed last Tuesday at $2.89. According to TipRanks.com, Chen is a 5-star analyst with an average return of 27.8% and a 38.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Clearside Biomedical with a $11.75 average price target, representing a 309.4% upside.

Austin Angelo on TipRanks | December 22, 2021

Wedbush Keeps a Buy Rating on Clearside Biomedical (CLSD)

In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report), with a price target of $9.00. The company's shares closed last Tuesday at $2.93. According to TipRanks.com, Argyrides is a 1-star analyst with an average return of -3.9% and a 0.0% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Kala Pharmaceuticals, Unity Biotechnology, and Graybug Vision. Currently, the analyst consensus on Clearside Biomedical is a Strong Buy with an average price target of $11.75, representing a 309.4% upside. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $11.

Brian Anderson on TipRanks | December 21, 2021

Clearside Biomedical (CLSD) Receives a Hold from Needham

Needham analyst Serge Belanger maintained a Hold rating on Clearside Biomedical (CLSD – Research Report) today. The company's shares closed last Tuesday at $2.74, close to its 52-week low of $1.92. According to TipRanks.com, Belanger is a 2-star analyst with an average return of 0.6% and a 37.1% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and KalVista Pharmaceuticals. Clearside Biomedical has an analyst consensus of Strong Buy, with a price target consensus of $11.75. See today’s best-performing stocks on TipRanks >> The company has a one-year high of $7.73 and a one-year low of $1.92.

Brian Anderson on TipRanks | December 21, 2021

JMP Securities Thinks Clearside Biomedical’s Stock is Going to Recover

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report), with a price target of $11.00. The company's shares closed last Tuesday at $2.74, close to its 52-week low of $1.92. According to TipRanks.com, Wolleben is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.3% and a 31.3% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals. Currently, the analyst consensus on Clearside Biomedical is a Strong Buy with an average price target of $11.75, a 309.

Brian Anderson on TipRanks | December 21, 2021

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

- Suprachoroidal Injection of CLS-AX 0.1 mg Dose Well-Tolerated in Cohort 2 with No Treatment Related Adverse Events –- Consistent Safety Profile Observed in Cohorts 1 and 2 Supports Advancement to Cohort 3 -- Webcast and Conference Call Today at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Peter Kaiser, M.D. - ALPHARETTA, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies t

Yahoo | December 21, 2021

Clearside Biomedical Added to the Nasdaq Biotechnology Index

ALPHARETTA, Ga., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that the Company will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021. The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Sto

Yahoo | December 13, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6274 seconds.